Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2652-2658

  Clemmons, David R ^a   Sleevi, M ^b   Allan, G ^b   Sommer, A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Insmed Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; HUMAN INSULIN; INSULIN; PLACEBO; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ADOLESCENT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

EID: 34447120710     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2699     Document Type: Article

References (29)

1. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC 1994 Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205-210
2. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR 1996 Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100
3. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kippes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP 1994 Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 43:369-374
4. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER 1992 Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90:2234-2241
5. Carroll PV, Christ ER, Umpleby AM, Gowrie I, Jackson N, Bowes SB, Hovorka R, Croos P, Sonksen PH, Russell-Jones DL 2000 IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes 49:789-796
6. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS 1994 Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest 93:1131-1139
7. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB 1993 The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:678-681
8. Crowne EC, Samra JS, Cheetham T, Watts A, Holly JM, Dunger DB 1998 Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 47:31-38
9. Quattrin T, Thrailkill K, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Giltinan D, Gesundheit N, Martha Jr P 1997 Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 20:374-380
10. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha Jr PM 1999 Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 22:585-592
11. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J 2000 The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85:1518-1524
12. Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allen G 2005 Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274
13. Cusi K, DeFronzo R 2000 Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85:3077-3084
14. Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB 1998 Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 47:1481-1489
15. Federici M, Giaccari A, Hribal ML, Giovannone B, Lauro D, Morviducci L, Pastore L, Tamburrano G, Lauro R, Sesti G 1999 Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes 48:2277-2285
16. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D 2004 Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96-105
17. Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB 2004 Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 89:4634-4641
18. Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopieto S, Clemmons D, Yakar S, LeRoith D 2006 Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619-2630
19. rhIGF-I co Therapy with Insulin Subgroup, rhIGF-I improves glucose control in insulin requiring type 2 diabetes. Proc of the 5th Annual Meeting of The American Diabetes Association, San Antonio, TX, 1997, p 582 (Abstract)
20. Jacob RJ, Sherwin RS, Bowen L, Fryburg D, Fagin KD, Tamborlane WV, Shulman GI 1991 Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats. Am J Physiol 260:E262-E268
21. Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS 1989 Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 83:1717-1723
22. Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, LeRoith D, Kahn CR, Cantley LC, Friedman JE, Draznin B 2005 Increased P85α is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280:37489-37494
23. Gerich JE, Meyer C, Woerle HJ, Stumvoll M 2001 Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382-391
24. Stumvoll M, Meyer C, Perriello G, Kreider M, Welle S, Gerich J 1998 Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol 274:E817-E826
25. Cingel-Ristic V, Flyvbjerg A, Drop SL 2004 The physiological and pathophysiological roles of the GH/IGF-axis in the kidney: lessons from experimental rodent models. Growth Horm IGF Res 14:418-430
26. Nakae J, Kido Y, Accili D 2001 Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22:818-835
27. Hartman ML, Clayton PE, Johnson ML, Celniker A, Perlman AJ, Alberti KG, Thorner MO 1993 A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest 91:2453-2462
28. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR 1993 Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 91:391-396
29. Clemmons DR, Sleevi M, Busby Jr WH 2005 Recombinant, nonglycosylated human insulin-like growth factor-binding protein-3 (IGFBP-3) is degraded preferentially after administration to type II diabetics, resulting in increased endogenous glycosylated IGFBP-3. J Clin Endocrinol Metab 90:6561-6568